期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

树突状细胞疫苗治疗恶性淋巴瘤的进展 被引量：2

Dendritic cell-based immunotherapy for malignant lymphoma
原文传递
导出
摘要 目前针对恶性淋巴瘤（ML）的治疗方案还不是十分有效，因此研发治疗淋巴瘤的新型药物具有重要意义。树突状细胞作为一类抗原递呈细胞，目前已开展了肿瘤抗原冲击树突状细胞（DC）免疫治疗ML的研究。从ML相关的各种抗原类型、DC疫苗的制备及临床试验研究等方面阐述近年来DC疫苗免疫治疗ML的进展，并探讨了DC疫苗的应用前景。 Due to therapeutic regimens for patients with malignant lymphoma （ML） is currently unsatisfactory, it is important to develop new complementary therapies for longer disease-free survival. Dendritic cells （DC） are specialized antigen-presenting cells of immune system and vaccination with tumor antigen-pulsed DC has been applied to treat patients for ML. In this review, we summarize various types of ML-associated antigens and clinical trials on DC-based immunotherapy in ML, and discuss the development of DC immunotherapy for ML patients in future.
作者 刘丽(综述) 范振芳(综述) 朱学军(审校)
机构地区 南京中医药大学附属江苏省中医院细胞与分子生物实验室 南京中医药大学附属江苏省中医院血液科
出处 《白血病．淋巴瘤》 CAS 2009年第8期502-505,共4页 Journal of Leukemia & Lymphoma
关键词 淋巴瘤 树突细胞 免疫疗法 Lymphoma Dendritic cells Immunotherapy
分类号 R733.4 [医药卫生—肿瘤] R392.12 [医药卫生—免疫学]
  • 相关文献

参考文献24

  • 1宋飞雪,张筠.树突状细胞及其在血液系统肿瘤免疫治疗中的应用[J].白血病．淋巴瘤,2004,13(1):55-58. 被引量：2
  • 2王志红,冯凯,陈虎.树突状细胞在肿瘤免疫中的研究进展[J].白血病．淋巴瘤,2005,14(2):119-121. 被引量：3
  • 3Redfern CH, Guthrie TH, Bessudo A, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol, 2006, 24:3107-3112.
  • 4Timmerman JM, Singh G, Hermanson G, etal. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res, 2002, 62: 5845-5852.
  • 5Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood, 2002, 99: 1517-1526.
  • 6Bae J, Martinson JA, Klingemann HG, et al. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Cfin Cancer Res, 2005, 11: 1629-1638.
  • 7lnozume T, Mitsui H, Okamoto T, et al. Dendritic cells transduced with autoantigen FCRLA induce cytotoxic lymph~ytes and vaccinate against murine B-cell lymphoma. J Invest Dermatol, 2007, 127: 2818-2822.
  • 8Greiner J, Li L, Ringhoffer M, et al. Identification and characterization of epitopes of the receptor for hyaluronic acid mediated motility (RHAMM/CD168) recognized by CD8^+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood, 2005, 106:938 - 945.
  • 9Giannopoulos K, Li L, Bojarska-Junak A, et al. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol, 2006, 29: 95-103.
  • 10Nagaraj S, Pisarev V, Kinarsky L, et al. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother, 2007, 30: 169-179.

二级参考文献14

  • 1O'Neill D W, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer [J]. Blood, 2004,104(8): 2235 -2246.
  • 2Lagaraine C, Lebranchu Y. Effects of immunosuppressive drugs on dendritic cells and tolerance induction[J]. Translantation,2003,75(9suppl):3s-7s.
  • 3Andre F, Schartz N E, Chaput N, et al.Tumor- derived exosomes:a new source of tumor rejection antigens[J]. Vaccine, 2002,20(suppl 1):A28-31.
  • 4Andre F, Schartz N E, Movassagh M,et al.Maligant effusions and immunogenic tumor-derived exosomes[J]. Lancet, 2002,360 ( 9329 ) :295-305.
  • 5Miller G, Lahrs S, Shah A B, et al. Optimization of dendritic cell maturation and gene transfer by recombinant adenovirus [J].Cancer Immunol Immunother, 2003, 52(6):387 -395.
  • 6Jeannin P, Magistrelli G, Goetsch L, et al.Outer membrane protein A (ompA):a new pathogen-associated molecular pattern that interacts with antigen presenting cells-impact on vaccine strategies[J]. Vaccine, 2002, 20(suppl 1):A23-27.
  • 7Vegh Z, Mazumder A. Generation of tumor cell lysate - loaded dendritic cells preprogrammed for IL-12 productio and augmented T cell response [J]. Cancer Immunol Immunother, 2003, 52(2): 67-79.
  • 8Sandra S, Andrees W, Dierer K, et al. Induction of cytoxic T - cell responses against the oncofetal antigen- immature laminin receptor for the treatment of hematologic malignancies[J]. Blood, 2003, 102 ( 13 ) :1116-1121.
  • 9Susanne M S, Kerstin S, Martin R M,et al.Survivin is a shared tumor - associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic Tcells[J]. Blood, 2003, 102(2): 571-576.
  • 10Silvia B, Katia P, Claudia M, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hemotopoietic transplantation[J]. Blood, 2003, 102(10):3807-3814.

共引文献3

同被引文献30

  • 1Liu C, Yu S, Kappes J, et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host [J]. Blood, 2007, 109(10): 4336-4342.
  • 2Zumsteg A, Baeriswyl V, Imaizumi N, et al. Myeloid cells contribute to tumor lymphangiogenesis [ J ]. PLoS One, 2009, 4 ( 9 ) : e7067-7074.
  • 3Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1^+/CD11 b ^+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity [J]. Clin Cancer Res, 2005, 11(18) : 6713 -6721.
  • 4Bauer C, Bauernfeind F, Sterzik A, et al. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model [ J ]. Gut, 2007, 56 ( 9 ) : 1275-1282.
  • 5Hirooka Y, Itoh A, Kawashima H, et al. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer[J].Pancreas, 2009, 38 ( 3 ) : e69-74.
  • 6Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells [J]. Nat Med, 1996, 2(1) : 52-58.
  • 7Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients [ J ]. Blood, 2002, 99 ( 5 ) : 1517-1526.
  • 8Adam C, Mysliwietz J, Mocikat R, et al. Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine [ J]. J Transl Med, 2007, 5 (1) : 16-26.
  • 9Di Nicola M, Zappasodi R, Carlo-Stella C, et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study [ J ]. Blood, 2009,113(1) : 18-27.
  • 10Strober S. Natural suppressor(NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships[J].Annu Rev Immunol, 2009, 113(1): 18-27.

引证文献2

二级引证文献4

白血病．淋巴瘤
2009年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部